Targeting Kynurenine Aminotransferase II in P... [Schizophr Bull. 2014] - PubMed - NCBI
More on KYNA this is a potential drug to block it already being developed. You know I think its funny when they say there are no new drugs in the pipeline when I see new stuff every day but its at the lab level and no where neat clinical trials yet. Part of the problem with any of these new drugs is that they are likely to work on only a subset of the population. So there was one that acted on GRM3 the metabotropic glutamate receptor but they compared it directly to the D2 blockers we have now and it didn't perform as well so they shelved it. To me that doesn't suggest that it doesn't work so much as it may work on a different group of people for example the treatment resistant individuals that have COMT and GRM3 mutations it might be a lifesaving drug for them. I honestly wonder why they don't use treatment resistant individuals as a starting point but suspect it has to do with ability to consent and other ethical issues but if it were me I would try anything at that point. I mean the rest of everyone the D2 blockers work for it is really just an issue of making a slightly better drug for them or is it about helping people who can't be helped with current therapies?